Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

113.15
-1.4800-1.29%
Post-market: 112.81-0.3400-0.30%16:15 EDT
Volume:900.88K
Turnover:101.58M
Market Cap:9.41B
PE:-35.23
High:114.50
Open:114.50
Low:110.29
Close:114.63
52wk High:130.05
52wk Low:47.86
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.40
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.23
PE(LYR):-30.66

Loading ...

Kymera Therapeutics Price Target Raised to $144.00/Share from $123.00 by B of a Securities

Dow Jones
·
Yesterday

BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123

MT Newswires Live
·
Sep 14

Wolfe upgrades Kymera Therapeutics to Outperform on potential upside

TIPRANKS
·
Sep 10

Kymera Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Sep 10

J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
Sep 04

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
Sep 03

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT Newswires Live
·
Sep 02

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Sep 02

Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121

THOMSON REUTERS
·
Sep 02

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

THOMSON REUTERS
·
Sep 01

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewswire
·
Sep 01

Kymera Therapeutics Price Target Raised to $151.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Aug 27

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06